Page 20 - John More News Today

Investegate announcements from Emmerson PLC, Director/PDMR Shareholding

FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa

FDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa PDUFA date of DUBLIN, Ireland, and Boston MA, June 3, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, today announces that the U.S. Food and Drug Administration (“FDA”) has granted Priority Review for Amryt’s New Drug Application (“NDA”...

© Mhairi Edwards/DCT Media John with some sconezones. It’s not every day that people get to turn their passion into a business. But for John More in Bridge of Earn, his love of scones is proving to be a big hit in the local community. These “sconezones” have been making a name for their creator John More, of Bridge of Earn bakery Johns Scone Mad, who turned his passion for making scones into a thriving business two years ago. Following The Courier’s story on his new creation, John has ...

  OnTheMarket plc, the majority agent-owned company which operates the OnTheMarket.com   property portal, is pleased to announce, further to the announcement of 22 March 2021, that it has now completed the acquisition of Glanty Ltd ("Glanty").   The initial consideration of £1,533,477 (the "Initial Consideration") required to be paid by OnTheMarket under the share purchase agreement is being satisfied by way of the issue of 1,528,832 ordinary s...

St Brides Partners (Financial PR/IR) Megan Dennison / Susie Geliher   Notes to Editors Emmersons primary focus is on developing the Khemisset project ("Khemisset" or the "Project") located in Northern Morocco.  The Project has a large JORC Resource Estimate (2012) of 537Mt @ 9.24% K 2O and significant exploration potential with an accelerated development pathway targeting a low capex, high margin mine. Khemisset is perfectly located to cap...

Subscription Notification We have noticed that there is an issue with your subscription billing details. Please update your billing details here Please update your billing information The subscription details associated with this account need to be updated. Please update your billing details here to continue enjoying your subscription. Your subscription will end shortly Please update your billing details here to continue enjoying your access to the most informative and considered journalism in ...

Investegate announcements from Amryt Pharma plc, Amryt Reports Record Q1 2021 Financial and Operating Results

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any natio...

o  Significantly reduced up-front capex of US$254.6m (pre-contingency) o  Potential for subsequent phases to be funded from internal cash flows o  Estimated  NPV o  Forecast EBITDA in first full year of phase 4 production of US$491.4m · Demonstration of flexibility and additional potential of Khemisset · Emmerson to continue Project development utilising outputs of this phased approach study   Ove...